LTZ Therapeutics Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 40

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $38M

  • Investors
  • 19

LTZ Therapeutics General Information

Description

Developer of an immunotherapy-focused biotechnology platform designed to develop myeloid engager therapies for oncology and autoimmune diseases. The company offers a universal myeloid cell engager platform with immune cell targeting capabilities, enabling patients with cancer and autoimmune conditions to access therapies aimed at improving clinical outcomes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1100 Island Drive
  • Suite 103
  • Redwood City, CA 94065
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 1100 Island Drive
  • Suite 103
  • Redwood City, CA 94065
  • United States

LTZ Therapeutics Timeline

2023202420252026
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

LTZ Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC (Series B) 06-May-2026 $38M Completed Generating Revenue
4. Early Stage VC (Series A1) 23-Apr-2025 Completed Generating Revenue
3. Early Stage VC (Series A) 29-Jul-2024 Completed Generating Revenue
2. Early Stage VC 30-May-2023 $10M $27M Completed Generating Revenue
1. Early Stage VC 06-Apr-2022 $17M $17M Completed Generating Revenue
To view LTZ Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

LTZ Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an immunotherapy-focused biotechnology platform designed to develop myeloid engager therapies for oncology
Drug Discovery
Redwood City, CA
40 As of 2026

San Carlos, CA
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

LTZ Therapeutics Competitors (3)

One of LTZ Therapeutics’s 3 competitors is Dren Bio, a Venture Capital-Backed company based in San Carlos, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dren Bio Venture Capital-Backed San Carlos, CA
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Kite Pharma Formerly VC-backed Santa Monica, CA
You’re viewing 3 of 3 competitors. Get the full list »

LTZ Therapeutics Patents

LTZ Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026151977-A1 Multispecific antibodies targeting egfr and clec5a and the uses thereof Pending 10-Jan-2025
WO-2026151957-A1 Multispecific antibodies targeting epcam and clec5a and the uses thereof Pending 10-Jan-2025
EP-4792891-A3 Multispecific antibodies and uses thereof Pending 12-Jul-2024
US-20250304679-A1 Multispecific antibodies targeting cd79b and cd3 and the uses thereof Pending 02-Apr-2024
US-20250304687-A1 Multispecific antibodies targeting cd79b/cd3 and the uses thereof Pending 02-Apr-2024 G01N33/6854
To view LTZ Therapeutics’s complete patent history, request access »

LTZ Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

LTZ Therapeutics Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds
Boyu Capital Asset Manager Minority
Hillhouse Capital PE/Buyout Minority
iFly PE-Backed Company Minority
5Y Capital Venture Capital Minority
Hillhouse Investment Group PE/Buyout Minority
You’re viewing 5 of 19 investors. Get the full list »

LTZ Therapeutics FAQs

  • When was LTZ Therapeutics founded?

    LTZ Therapeutics was founded in 2022.

  • Where is LTZ Therapeutics headquartered?

    LTZ Therapeutics is headquartered in Redwood City, CA.

  • What is the size of LTZ Therapeutics?

    LTZ Therapeutics has 40 total employees.

  • What industry is LTZ Therapeutics in?

    LTZ Therapeutics’s primary industry is Drug Discovery.

  • Is LTZ Therapeutics a private or public company?

    LTZ Therapeutics is a Private company.

  • What is LTZ Therapeutics’s current revenue?

    The current revenue for LTZ Therapeutics is .

  • How much funding has LTZ Therapeutics raised over time?

    LTZ Therapeutics has raised $126M.

  • Who are LTZ Therapeutics’s investors?

    Boyu Capital, Hillhouse Capital, iFly, 5Y Capital, and Hillhouse Investment Group are 5 of 19 investors who have invested in LTZ Therapeutics.

  • Who are LTZ Therapeutics’s competitors?

    Dren Bio, CytomX Therapeutics, and Kite Pharma are competitors of LTZ Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process